Foghorn Therapeutics (FHTX) Revenue (2020 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Revenue of $3.3 million for Q1 2026, down 45.11% year-over-year from $6.0 million in Q1 2025, and down 64.67% quarter-over-quarter from $9.2 million in Q4 2025.
Foghorn Therapeutics (FHTX) Revenue (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Revenue history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.
- In Q1 2026, Revenue fell 45.11% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $28.2 million (up 20.08% YoY), while the FY2025 annual figure was $30.9 million, up 36.75% from the prior year.
- Revenue for Q1 2026 stood at $3.3 million, down from $9.2 million in the prior quarter.
- The five-year high for Revenue was $17.5 million in Q3 2023, with the low at $2.9 million in Q4 2024.
- The 5-year median for Revenue is $5.8 million (2023), against an average of $6.5 million.
- The sharpest annual moves came in 2022 and 2024: Revenue surged 16080.49% in 2022, then sank 55.33% in 2024.
- Foghorn Therapeutics' Revenue stood at $4.2 million in 2022, then surged by 37.88% to $5.8 million in 2023, then slumped by 50.49% to $2.9 million in 2024, then surged by 223.77% to $9.2 million in 2025, then tumbled by 64.67% to $3.3 million in 2026.
- Business Quant data shows FHTX's Revenue at $3.3 million in Q1 2026, $9.2 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Foghorn Therapeutics | 367.55 Mn | 299.47 Mn | - | 16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.07 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 8.15 Mn |
| Jun 30, 2025 | 7.56 Mn |
| Mar 31, 2025 | 5.95 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 7.81 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 5.05 Mn |
| Dec 31, 2023 | 5.77 Mn |
| Sep 30, 2023 | 17.48 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 4.18 Mn |
| Sep 30, 2022 | 6.63 Mn |
| Jun 30, 2022 | 4.49 Mn |
| Mar 31, 2022 | 3.92 Mn |
| Dec 31, 2021 | 713,000.00 |
| Sep 30, 2021 | 41,000.00 |